DOP2013000029A - Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos - Google Patents

Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Info

Publication number
DOP2013000029A
DOP2013000029A DO2013000029A DO2013000029A DOP2013000029A DO P2013000029 A DOP2013000029 A DO P2013000029A DO 2013000029 A DO2013000029 A DO 2013000029A DO 2013000029 A DO2013000029 A DO 2013000029A DO P2013000029 A DOP2013000029 A DO P2013000029A
Authority
DO
Dominican Republic
Prior art keywords
n3pglu
amiloide
peptidic
same
antibodies
Prior art date
Application number
DO2013000029A
Other languages
English (en)
Inventor
Ying Tang
Jirong Lu
Ronald Bradley Demattos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2013000029A publication Critical patent/DOP2013000029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos A3 anti-N3pGlu o fragmento de unión al antígeno de los mismos. Además, la presente invención proporciona el uso de los anticuerpos Aí3 anti-N3pGlu o fragmento de unión al antígeno de los mismos para el tratamiento de la enfermedad de Alzheimer.
DO2013000029A 2010-08-12 2013-02-05 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos DOP2013000029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
DOP2013000029A true DOP2013000029A (es) 2013-03-15

Family

ID=44543826

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000029A DOP2013000029A (es) 2010-08-12 2013-02-05 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Country Status (38)

Country Link
US (2) US8679498B2 (es)
EP (3) EP3339323B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN103068848B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK2603523T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2764728T3 (es)
GT (1) GT201300036A (es)
HK (1) HK1180703A1 (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE028678T2 (es)
IL (2) IL224030B (es)
LT (2) LT3339323T (es)
MA (1) MA34461B1 (es)
ME (3) ME03661B (es)
MX (2) MX342782B (es)
MY (2) MY181969A (es)
NO (1) NO3042917T3 (es)
NZ (2) NZ626665A (es)
PE (1) PE20130817A1 (es)
PL (3) PL3339323T3 (es)
PT (2) PT3042917T (es)
RS (3) RS57026B1 (es)
SG (2) SG10201509330XA (es)
SI (3) SI3042917T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
DK2603523T3 (en) * 2010-08-12 2016-03-21 Lilly Co Eli ANTI-N3pGlu-AMYLOIDBETAPEPTIDANTISTOFFER AND USES THEREOF
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
ES2779977T3 (es) 2014-07-10 2020-08-21 Univ Zuerich Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
SI3353212T1 (sl) * 2015-09-23 2022-01-31 Regeneron Pharmaceuticals, Inc., Optimizirana bispecifična protitelesa proti-CD3 in njihove uporabe
JP6993699B2 (ja) 2016-01-11 2022-02-03 ウニヴェルズィテート・ツューリヒ ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740944A (zh) * 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CA3032692A1 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
WO2018034977A1 (en) 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
CN109803653A (zh) 2016-10-28 2019-05-24 H.隆德贝克有限公司 包括给予咪唑并吡嗪酮的组合治疗
US10905688B2 (en) 2016-10-28 2021-02-02 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
SG11202001281WA (en) 2017-08-22 2020-03-30 Biogen Ma Inc Pharmaceutical compositions containing anti-beta amyloid antibodies
RS62551B1 (sr) 2017-12-14 2021-12-31 H Lundbeck As Kombinovane terapije koje obuhvataju primenu 1h-pirazolo[4,3-b]piridina
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3728250A1 (en) 2017-12-20 2020-10-28 H. Lundbeck A/S PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS
US20220177560A1 (en) * 2019-03-26 2022-06-09 Janssen Pharmaceutica Nv Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
US20230250193A1 (en) * 2020-06-17 2023-08-10 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
EP4185612A1 (en) 2020-07-23 2023-05-31 Othair Prothena Limited Anti-abeta antibodies
CA3192910A1 (en) 2020-10-02 2022-04-07 Brian David BOWES Methods for reducing host cell protein content in protein purification processes
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
AU2022371475A1 (en) 2021-10-22 2024-05-09 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
WO2023076970A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
AU2022379194A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
CN118475610A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
MX2024005145A (es) 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a la interleucina-34.
AU2023216231A1 (en) 2022-02-03 2024-08-01 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
WO2024020470A1 (en) * 2022-07-21 2024-01-25 Eli Lilly And Company PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
AU2005217596B2 (en) * 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
AP2007003890A0 (en) * 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
AU2009257170B2 (en) 2008-06-12 2014-06-12 Affiris Ag Compounds for treating symptoms associated with Parkinson's disease
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
JP5828762B2 (ja) * 2008-07-21 2015-12-09 プロビオドルグ エージー 診断用抗体アッセイ
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
DK2603523T3 (en) * 2010-08-12 2016-03-21 Lilly Co Eli ANTI-N3pGlu-AMYLOIDBETAPEPTIDANTISTOFFER AND USES THEREOF

Also Published As

Publication number Publication date
ME03032B (me) 2018-10-20
SI3042917T1 (en) 2018-04-30
JP2013536191A (ja) 2013-09-19
DK2603523T3 (en) 2016-03-21
EP3339323A1 (en) 2018-06-27
AU2011289629A1 (en) 2013-02-14
EA201270813A1 (ru) 2013-05-30
SI3339323T1 (sl) 2019-12-31
US20130142806A1 (en) 2013-06-06
CN105111308A (zh) 2015-12-02
CA2805114C (en) 2017-12-05
CO6670526A2 (es) 2013-05-15
NZ626665A (en) 2016-04-29
MA34461B1 (fr) 2013-08-01
DK3042917T3 (en) 2018-04-23
EA023021B1 (ru) 2016-04-29
BR112013004056B1 (pt) 2022-05-17
CA2805114A1 (en) 2012-02-16
PE20130817A1 (es) 2013-07-18
IL285226B (en) 2022-10-01
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
CY1122458T1 (el) 2021-01-27
GT201300036A (es) 2014-07-16
BR112013004056B8 (pt) 2022-10-18
CN103068848A (zh) 2013-04-24
PL2603523T3 (pl) 2016-07-29
PL3339323T3 (pl) 2020-05-18
NO3042917T3 (es) 2018-07-21
IL285226A (en) 2021-09-30
IL285226B2 (en) 2023-02-01
US8961972B2 (en) 2015-02-24
ME03661B (me) 2020-07-20
ES2764728T3 (es) 2020-06-04
ES2564252T3 (es) 2016-03-21
CR20130016A (es) 2013-03-21
EP2603523A1 (en) 2013-06-19
MY163521A (en) 2017-09-15
SI2603523T1 (sl) 2016-04-29
CN105111308B (zh) 2019-03-12
HUE028678T2 (en) 2016-12-28
JP6395755B2 (ja) 2018-09-26
KR20130051989A (ko) 2013-05-21
EP2603523B1 (en) 2016-01-27
EP3042917B1 (en) 2018-02-21
ECSP13012436A (es) 2013-03-28
ME02352B (me) 2016-06-20
LT3042917T (lt) 2018-05-10
JP2016179985A (ja) 2016-10-13
JP5980207B2 (ja) 2016-08-31
UA107600C2 (uk) 2015-01-26
MY181969A (en) 2021-01-15
HRP20160151T1 (hr) 2016-03-11
HUE037524T2 (hu) 2018-09-28
LT3339323T (lt) 2020-02-10
HRP20192233T1 (hr) 2020-03-06
BR112013004056A2 (pt) 2020-08-04
CY1120144T1 (el) 2018-12-12
SG10201509330XA (en) 2015-12-30
PT3339323T (pt) 2020-01-14
PL3042917T3 (pl) 2018-07-31
EP3042917A1 (en) 2016-07-13
RS54685B1 (en) 2016-08-31
PT3042917T (pt) 2018-05-02
ZA201300437B (en) 2014-06-25
AU2011289629B2 (en) 2014-07-03
EP3339323B1 (en) 2019-11-13
CN103068848B (zh) 2015-11-25
HK1180703A1 (zh) 2013-10-25
RS59652B1 (sr) 2020-01-31
ES2664128T3 (es) 2018-04-18
DK3339323T3 (da) 2020-01-20
MX355268B (es) 2018-04-11
MX342782B (es) 2016-10-12
US20140065138A1 (en) 2014-03-06
MX2013001716A (es) 2013-10-28
RS57026B1 (sr) 2018-05-31
CL2013000390A1 (es) 2014-03-21
HRP20180616T1 (hr) 2018-07-13
IL224030B (en) 2022-04-01
WO2012021469A1 (en) 2012-02-16
US8679498B2 (en) 2014-03-25
NZ606095A (en) 2014-11-28

Similar Documents

Publication Publication Date Title
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CL2019000643A1 (es) Anticuerpos de unión a cd3.
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
AU2018256498A1 (en) Antibodies to amyloid beta
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112014011594A2 (pt) anticorpos anti-il-36r
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
BR112014011404A2 (pt) moléculas de anticorpos com especificidade para o ox40 humano
CU20120095A7 (es) Antagonistas de pcsk9
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
AR124605A2 (es) Anticuerpos anti-il-36r
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
TH128722A (th) ฮิวมาไนซ์แอนติบอดีที่จำเพาะต่อรูปโปรโตไฟบริลลาร์ของบีตา-อมัยลอยด์เพพไทด์
UA111322C2 (uk) Антитіло, що зв'язується переважно з позаклітинним доменом 4 людського csf-1r, і його застосування